Inspire Medical Systems Inc
$ 64.51
-5.20%
27 Feb - close price
- Market Cap 1,874,431,000 USD
- Current Price $ 64.51
- High / Low $ 65.99 / 62.10
- Stock P/E 13.19
- Book Value 27.33
- EPS 4.89
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.20 %
- 52 Week High 189.49
- 52 Week Low 53.11
About
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. The company is headquartered in Golden Valley, Minnesota.
Analyst Target Price
$77.86
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-11-03 | 2025-08-04 | 2025-05-05 | 2025-02-10 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-02-06 | 2023-11-07 | 2023-08-01 | 2023-05-02 |
| Reported EPS | 1.65 | 0.38 | 0.45 | 0.1 | 1.15 | 0.6 | 0.32 | -0.34 | 0.49 | -0.29 | -0.41 | -0.53 |
| Estimated EPS | 0.6789 | -0.19 | 0.2 | -0.23 | 0.72 | 0.06 | -0.14 | -0.65 | -0.09 | -0.58 | -0.57 | -0.66 |
| Surprise | 0.9711 | 0.57 | 0.25 | 0.33 | 0.43 | 0.54 | 0.46 | 0.31 | 0.58 | 0.29 | 0.16 | 0.13 |
| Surprise Percentage | 143.0402% | 300% | 125% | 143.4783% | 59.7222% | 900% | 328.5714% | 47.6923% | 644.4444% | 50% | 28.0702% | 19.697% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.081 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INSP
2026-02-27 22:52:10
Evercore ISI maintained an Outperform rating for Inspire Medical Systems (INSP) on February 27, 2026, after the CMS announced new HCPCS codes, three of which are relevant for the company's hypoglossal nerve stimulation devices. This coding clarity is expected to reduce administrative friction and support procedure adoption, leading to a positive market reaction with INSP shares moving up 5.59%. Meyka AI also assigns INSP an 'A' grade, reinforcing the positive outlook primarily driven by potential revenue expansion from clarified reimbursement.
2026-02-27 17:51:40
Inspire Medical Systems (NYSE:INSP) shares gapped down on Friday, opening at $63.02 after closing at $68.05. This occurred despite reporting a strong quarter with EPS of $1.65 (beating estimates of $0.69) and revenue of $269.08 million, a 12.2% increase year-over-year. The stock has a consensus "Hold" rating from analysts with an average price target of $104.82, and institutional ownership remains high at 94.91%.
2026-02-27 17:51:40
Shares of Inspire Medical Systems (INSP) fell 7.5% following a key inflation report showing the Producer Price Index rose more than anticipated, sparking concerns about delayed interest rate cuts. This downturn comes after the stock had previously gained 19.7% due to news that the CMS is assigning specific C-codes for the Inspire V device, resolving reimbursement uncertainties. Despite earlier regulatory wins, INSP is down 31.1% year-to-date and 65.7% from its 52-week high, with the market reacting to broader economic concerns.
2026-02-27 15:51:40
Inspire Medical Systems (INSP) experienced a 14.85% jump in its share price following the approval of new CMS billing codes for hypoglossal nerve stimulation procedures, effective January 2026. Despite previous negative long-term returns, this news resolves reimbursement uncertainty for its obstructive sleep apnea therapy, suggesting improving momentum. The stock is currently trading at US$68.05, representing an indicated 51.13% intrinsic discount and about 14% below the analyst target, leading investors to question if this presents a new entry point.
2026-02-27 11:51:40
Oppenheimer has reiterated its Perform rating on Inspire Medical Systems (NYSE:INSP) after the Centers for Medicare & Medicaid Services proposed new facility codes for hypoglossal nerve stimulation devices, effective retroactive to January 1, 2026. While the temporary codes could map to existing APC rates of $31,500, the company faces mixed analyst reactions due to ongoing reimbursement challenges despite appearing undervalued according to InvestingPro.
2026-02-27 11:51:40
Inspire Medical Systems (INSP) stock surged 14.9% after reporting better-than-expected Q4 revenue and a significant 182% increase in Q4 net income per diluted share. Despite recent legal challenges and moderated revenue growth compared to previous years, investors are rewarding the company's improving profitability and strong unit economics, reflected in its 85.4% LTM gross margin. The company's 2026 revenue growth projection of 10-11% during its January presentation also contributed to renewed investor optimism.
